Long-term effects of anti-tumour necrosis factor therapy on weight in patients with rheumatoid arthritis

Clinical Rheumatology

Volumn 31, Issue 3, 2012, Pages 455-461

  Brown, Rachel A ^a   Spina, Domenico ^b   Butt, Sayqa ^a   Summers, Gregory D ^a  

^a ROYAL DERBY HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Anti tumour necrosis factor therapy; Body mass index; Rheumatoid arthritis; Rheumatoid cachexia; Weight

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; PREDNISOLONE; STEROID; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; CALCULATION; CONTROLLED STUDY; DRUG EFFECT; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; RHEUMATOID ARTHRITIS; TREATMENT DURATION; WEIGHT GAIN;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BODY MASS INDEX; BODY WEIGHT; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME;

EID: 84859752709     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-011-1863-6     Document Type: Article

References (26)

1. Munro R, Capell H (1997) Prevalence of low body mass in rheumatoid arthritis: association with the acute phase response. Ann Rheum Dis 56(5):326-329 (Pubitemid 27278522)
2. Helliwell M, Coombes EJ, Moody BJ, Batstone GF, Robertson JC (1984) Nutritional status in patients with rheumatoid arthritis. Ann Rheum Dis 43(3):386-390 (Pubitemid 14117907)
3. Fleming A, Crown JM, Corbett M (1976) Prognostic value of early features in rheumatoid disease. Br Med J 1(6020):1243-1245
4. Kaufmann J, Kielstein V, Kilian S, Stein G, Hein G (2003) Relation between body mass index and radiological progression in patients with rheumatoid arthritis. J Rheumatol 30(11):2350-2355 (Pubitemid 37413892)
5. Kaufmann JVA, Muller A (2001) Synovial collagen II degradation correlates inversely with the body mass index in rheumatoid arthritis. Z Rheumatol 60(Suppl 1):I/77
6. Westhoff G, Rau R, Zink A (2007) Radiographic joint damage in early rheumatoid arthritis is highly dependent on body mass index. Arthritis Rheum 56(11):3575-3582 (Pubitemid 350100690)
7. Walsmith J, Roubenoff R (2002) Cachexia in rheumatoid arthritis. Int J Cardiol 85(1):89-99
8. Giles JT, Ling SM, Ferrucci L, Bartlett SJ, Andersen RE, Towns M et al (2008) Abnormal body composition phenotypes in older rheumatoid arthritis patients: association with disease characteristics and pharmacotherapies. Arthritis Rheum 59(6):807-815 (Pubitemid 351847563)
9. Summers GD, Deighton CM, Rennie MJ, Booth AH (2008) Rheumatoid cachexia: a clinical perspective. Rheumatology (Oxford) 47(8):1124-1131 (Pubitemid 352038214)
10. Summers GD, Metsios GS, Stavropoulos-Kalinoglou A, Kitas GD (2010) Rheumatoid cachexia and cardiovascular disease. Nat Rev Rheumatol 6(8):445-451
11. Taylor PC, Feldmann M (2009) Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol 5 (10):578-582
12. Marcora SM, Chester KR, Mittal G, Lemmey AB, Maddison PJ (2006) Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. Am J Clin Nutr 84(6):1463-1472 (Pubitemid 44912832)
13. National Institute for Health and Clinical Excellence (2009) Rheumatoid arthritis: the management of rheumatoid arthritis in adults. Clinical Guidelines CG79. National Institute for Health and Clinical Excellence, London
14. Metsios GS, Stavropoulos-Kalinoglou A, Douglas KM, Koutedakis Y, NevillAM, Panoulas VF et al (2007) Blockade of tumour necrosis factor-alpha in rheumatoid arthritis: effects on components of rheumatoid cachexia. Rheumatology (Oxford) 46(12):1824-1827 (Pubitemid 350168299)
15. Alcorn N, Tierney A, Wu O, Gilmour H, Madhok R (2010) Impact of anti-tumour necrosis factor therapy on the weight of patients with rheumatoid arthritis. Ann Rheum Dis 69(8):1571
16. Engvall IL, Tengstrand B, Brismar K, Hafstrom I (2010) Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months. Arthritis Res Ther 12(5):R197
17. Briot K, Gossec L, Kolta S, Dougados M, Roux C (2008) Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-alpha treatment. J Rheumatol 35(5):855-861 (Pubitemid 351747128)
18. Briot K, Garnero P, Le Henanff A, Dougados M, Roux C (2005) Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor alpha treatment. Ann Rheum Dis 64(8):1137-1140 (Pubitemid 41113346)
19. Saraceno R, Schipani C, Mazzotta A, Esposito M, Di Renzo L, De Lorenzo A et al (2008) Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis. Pharmacol Res 57(4):290-295
20. Prignano F, Ricceri F, Pescitelli L, Buggiani G, Troiano M, Zanieri F et al (2009) Comparison of body weight and clinical-parameter changes following the treatment of plaque psoriasis with biological therapies. Curr Med Res Opin 25 (9):2311-2316
21. Esposito M, Mazzotta A, Saraceno R, Schipani C, Chimenti S (2009) Influence and variation of the body mass index in patients treated with etanercept for plaque-type psoriasis. Int J Immunopathol Pharmacol 22(1):219-225
22. Gisondi P, Cotena C, Tessari G, Girolomoni G (2008) Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol 22(3):341-344
23. Alcorn N, Saunders S, Madhok R (2009) Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. Drug Saf 32(12):1123-1134
24. Naranjo A, Sokka T, Descalzo MA, Calvo-Alen J, Horslev-Petersen K, Luukkainen RK et al (2008) Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 10(2):R30
25. Rall LC, Roubenoff R (2004) Rheumatoid cachexia: metabolic abnormalities, mechanisms and interventions. Rheumatology (Oxford) 43(10):1219-1223 (Pubitemid 39359292)
26. Seror R, Dougados M, Gossec L (2009) Glucocorticoid sparing effect of tumour necrosis factor alpha inhibitors in rheumatoid arthritis in real life practice. Clin Exp Rheumatol 27(5):807-813